Immunovant (NASDAQ:IMVT) Posts Quarterly Earnings Results, Beats Expectations By $0.11 EPS

Immunovant (NASDAQ:IMVT) announced its quarterly earnings data on Friday. The company reported ($0.61) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.11, FiscalAI reports. During the same quarter in the previous year, the business earned ($0.76) earnings per share.

Here are the key takeaways from Immunovant’s conference call:

• Phase 2 cutaneous sarcoidosis: BREPA 45 mg produced a ~21.6‑point placebo‑adjusted CSAMI improvement with a 100% ≥10‑point responder rate, rapid separation vs placebo, supportive PROs and no SAEs reported in the study.
• Development and catalyst cadence is heavy in 2026 — a phase 3 program for cutaneous sarcoidosis will start this year, an NDA is filed for dermatomyositis, NIU phase 3 readout is expected in H2 2026, and multiple other trials (mosliciguat, DTT‑RA, 1402 CLE) are fully enrolled or nearing data.
• Financially fortified: Roivant reported a consolidated cash balance of about $4.5 billion and non‑GAAP net loss of $167M for the quarter, which management says provides runway to multiple near‑term development and potential launches.
• Commercial opportunity: Management views BREPA as a multi‑indication orphan franchise (DM, NIU, CS) with high unmet need and expects orphan pricing levers if phase 3 results mirror the strong phase 2 outcomes.
• JV/accounting note: Priovant is 25% owned by Pfizer and Roivant will fully consolidate Priovant’s results while recording Pfizer’s share as a below‑the‑line minority interest; Pfizer’s early dilution protections are exhausted, so future capital raises could require Pfizer to match or lead to dilution.

Immunovant Stock Performance

IMVT opened at $27.05 on Friday. The stock has a market capitalization of $4.74 billion, a price-to-earnings ratio of -9.52 and a beta of 0.54. The company has a fifty day moving average of $25.61 and a 200 day moving average of $20.75. Immunovant has a fifty-two week low of $12.72 and a fifty-two week high of $27.80.

Insider Transactions at Immunovant

In related news, CTO Jay S. Stout sold 1,977 shares of the firm’s stock in a transaction on Wednesday, January 21st. The shares were sold at an average price of $26.03, for a total value of $51,461.31. Following the completion of the transaction, the chief technology officer directly owned 197,634 shares of the company’s stock, valued at approximately $5,144,413.02. This trade represents a 0.99% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider Tuyl Christopher Van sold 10,813 shares of the stock in a transaction on Thursday, December 18th. The shares were sold at an average price of $26.91, for a total transaction of $290,977.83. Following the transaction, the insider owned 149,930 shares of the company’s stock, valued at $4,034,616.30. This trade represents a 6.73% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders sold 63,868 shares of company stock valued at $1,538,470. 1.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Immunovant

Large investors have recently added to or reduced their stakes in the stock. Deep Track Capital LP boosted its holdings in shares of Immunovant by 2.4% in the 3rd quarter. Deep Track Capital LP now owns 9,728,845 shares of the company’s stock worth $156,829,000 after purchasing an additional 228,845 shares during the period. Armistice Capital LLC lifted its position in Immunovant by 12.2% in the third quarter. Armistice Capital LLC now owns 5,836,000 shares of the company’s stock worth $94,076,000 after buying an additional 636,000 shares during the last quarter. Two Seas Capital LP boosted its stake in Immunovant by 22.6% during the third quarter. Two Seas Capital LP now owns 2,762,040 shares of the company’s stock worth $44,524,000 after buying an additional 509,268 shares during the period. ADAR1 Capital Management LLC increased its position in Immunovant by 319.0% during the third quarter. ADAR1 Capital Management LLC now owns 2,241,753 shares of the company’s stock valued at $36,137,000 after acquiring an additional 1,706,687 shares during the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in shares of Immunovant by 48.6% in the first quarter. Goldman Sachs Group Inc. now owns 1,007,700 shares of the company’s stock valued at $17,222,000 after acquiring an additional 329,354 shares during the period. 47.08% of the stock is owned by institutional investors.

Analyst Ratings Changes

Several research analysts have recently weighed in on the company. The Goldman Sachs Group boosted their price target on Immunovant from $18.00 to $28.00 and gave the stock a “neutral” rating in a research note on Monday, December 15th. Weiss Ratings restated a “sell (d-)” rating on shares of Immunovant in a research note on Friday, January 9th. Guggenheim restated a “buy” rating and set a $41.00 price objective on shares of Immunovant in a research report on Thursday, December 18th. Truist Financial raised their target price on shares of Immunovant from $16.00 to $22.00 and gave the stock a “hold” rating in a report on Thursday, January 8th. Finally, Wolfe Research raised shares of Immunovant from a “peer perform” rating to an “outperform” rating and set a $50.00 target price for the company in a research report on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $30.78.

About Immunovant

Immunovant Inc is a clinical-stage biopharmaceutical company focused on the development of novel monoclonal antibody therapies that target the neonatal Fc receptor (FcRn) to treat severe autoimmune diseases. By inhibiting FcRn, Immunovant’s approach is designed to reduce levels of pathogenic immunoglobulin G (IgG) antibodies, which play a central role in the pathology of disorders such as myasthenia gravis and immune thrombocytopenia.

The company’s lead asset, efgartigimod, is an engineered Fc fragment that selectively binds to FcRn, accelerating the degradation of circulating IgG.